<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02020694</url>
  </required_header>
  <id_info>
    <org_study_id>752/11</org_study_id>
    <secondary_id>2011-003183-75</secondary_id>
    <nct_id>NCT02020694</nct_id>
  </id_info>
  <brief_title>Vitamin D Supplementation for the Prevention of Cardiovascular Risk</brief_title>
  <official_title>The Role of Vitamin D Supplementation in the Prevention of Cardiovascular Risk Factors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catholic University of the Sacred Heart</source>
  <brief_summary>
    <textblock>
      Hypovitaminosis D is highly prevalent in the general population, particularly in obese
      individuals. Besides being associated with obesity, vitamin D deficiency seems to be involved
      in the pathogenesis of insulin resistance and low-grade chronic inflammation. In addition, it
      has been reported that individuals with low vitamin D levels are at increased risk for
      cardiovascular diseases. A healthy diet and weight loss are cornerstones in the prevention of
      cardiovascular diseases. Vitamin D supplementation could increase the beneficial effects of
      these lifestyle interventions. The purpose of this study is to assess whether vitamin D
      supplementation in conjunction with a hypocaloric diet improves the cardiometabolic profile
      of overweight/obese subjects to a greater extent than diet alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in insulin sensitivity (M value)</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Insulin sensitivity will be measured with the hyperinsulinemic euglycemic clamp technique and expressed as M value, calculated from the glucose infusion rate during the last 30 min of the clamp.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in oral glucose tolerance</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Oral glucose tolerance will be assessed with a standard 2-hour oral glucose tolerance test (OGTT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body composition</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Body composition will be determined by using dual energy X-ray absorptiometry (DXA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in anthropometric parameters</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Weight, BMI, waist and hip circumference, waist/hip ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change form baseline in systolic and diastolic blood pressure</measure>
    <time_frame>Baseline, 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in phosphocalcic metabolism</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Serum vitamin D, PTH and calcium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in inflammatory markers</measure>
    <time_frame>Baseline, 3 months</time_frame>
    <description>Interleukin-6 (IL-6), IL-10, adiponectin, TNF-α, C-reactive protein (CRP) and fibrinogen</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Obesity</condition>
  <condition>Overweight</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Vitamin D and Diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cholecalciferol (vitamin D3) 25,000 I.U./2.5 mL oral solution. 25,000 I.U. (one bottle) per week.
Hypocaloric diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo &amp; Diet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral solution mimicking cholecalciferol (vitamin D3) 25,000 I.U./2.5 mL. One bottle per week.
Hypocaloric diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <arm_group_label>Vitamin D and Diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for vitamin D)</intervention_name>
    <arm_group_label>Placebo &amp; Diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI≥25 kg/m2

        Exclusion Criteria:

          -  Diabetes mellitus

          -  Chronic kidney disease

          -  Liver disease

          -  Cholestasis

          -  Cancer

          -  Chronic bowel disease

          -  Primary or secondary hyperparathyroidism

          -  Treatment with drugs that may affect insulin sensitivity, weight or calcium/vitamin D
             metabolism

          -  Laxative abuse

          -  Changes &gt;10% of usual body weight in the previous 6 months

          -  Alcohol or illicit drug abuse

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Giaccari, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University of the Sacred Heart</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Catholic University of Sacred Heart</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Muscogiuri G, Policola C, Prioletta A, Sorice G, Mezza T, Lassandro A, Della Casa S, Pontecorvi A, Giaccari A. Low levels of 25(OH)D and insulin-resistance: 2 unrelated features or a cause-effect in PCOS? Clin Nutr. 2012 Aug;31(4):476-80. doi: 10.1016/j.clnu.2011.12.010. Epub 2012 Jan 20.</citation>
    <PMID>22260937</PMID>
  </reference>
  <reference>
    <citation>Muscogiuri G, Sorice GP, Prioletta A, Policola C, Della Casa S, Pontecorvi A, Giaccari A. Will vitamin D reduce insulin resistance? Still a long way to go. Am J Clin Nutr. 2011 Mar;93(3):672-3; author reply 673-4. doi: 10.3945/ajcn.110.009068. Epub 2011 Jan 5.</citation>
    <PMID>21209228</PMID>
  </reference>
  <reference>
    <citation>Muscogiuri G, Sorice GP, Prioletta A, Policola C, Della Casa S, Pontecorvi A, Giaccari A. Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes: comment to Kayaniyil et al. Diabetes Care. 2010 Jul;33(7):e99; author reply e100. doi: 10.2337/dc10-0587.</citation>
    <PMID>20587719</PMID>
  </reference>
  <reference>
    <citation>Muscogiuri G, Sorice GP, Prioletta A, Policola C, Della Casa S, Pontecorvi A, Giaccari A. 25-Hydroxyvitamin D concentration correlates with insulin-sensitivity and BMI in obesity. Obesity (Silver Spring). 2010 Oct;18(10):1906-10. doi: 10.1038/oby.2010.11. Epub 2010 Feb 11.</citation>
    <PMID>20150902</PMID>
  </reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2013</study_first_submitted>
  <study_first_submitted_qc>December 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2013</study_first_posted>
  <last_update_submitted>February 2, 2015</last_update_submitted>
  <last_update_submitted_qc>February 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catholic University of the Sacred Heart</investigator_affiliation>
    <investigator_full_name>Andrea Giaccari</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Cardiovascular risk factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

